Lupin Reports 51.5% Surge in Q1 FY2026 Net Profit, Driven by Strong US and India Sales

Lupin Ltd has reported a strong start to the fiscal year, with net profit for Q1 FY2026 (April–June 2025) rising 51.5% year-on-year to ₹1,221.5 crore, compared to ₹805.5 crore in the same quarter last year.

The company's revenue from operations increased by 12% to ₹6,268.3 crore, up from ₹5,600.3 crore during Q1 FY2025.

Lupin’s EBITDA rose 38% to ₹1,806.3 crore, up from ₹1,308.8 crore in the year-ago period. The EBITDA margin expanded by 560 basis points to 29.3%, reflecting improved operational efficiencies. Research and development (R&D) spending stood at ₹484.4 crore, accounting for 7.9% of sales, compared to ₹350 crore (6.3% of sales) in Q1 of the previous fiscal.

Commenting on the results, Nilesh Gupta, Managing Director, Lupin, said:
"We continue to build strong business momentum, anchored by a robust product portfolio, improved efficiencies, and effective use of assets and investments. Our sharpened focus on compliance, innovation, and technology positions us well to unlock sustainable growth."

Regional Highlights:

United States:

• US sales rose 24.3% to ₹2,404.1 crore ($282 million), from ₹1,933.7 crore ($231 million) in Q1 FY2025.

• The US accounted for 39% of Lupin’s global sales.

• The company launched 3 new products in the US during the quarter.

• Lupin received 2 new ANDA approvals from the US FDA, bringing cumulative ANDA filings to 442, with 342 approvals as of June 30, 2025.

• Lupin now has 49 First-to-File (FTF) opportunities, including 19 exclusive FTFs.

• The company has filed 92 Drug Master Files (DMFs) in the US to date.

• With 139 generic products on the US market, Lupin continues to rank as the third-largest pharmaceutical company by prescriptions in both the US generics and overall prescription markets.

India:

• India sales grew by 7.8% year-on-year to ₹2,089.4 crore, from ₹1,938.1 crore in Q1 FY2025.

• India accounted for 34% of Lupin’s global sales.

• Formulations sales in India rose 8.6%, reflecting continued domestic demand and product performance.